About

Peter Magdy Abadir, M.D.

Associate Professor of Medicine, Johns Hopkins University
Co-Principal Investigator, Johns Hopkins Artificial Intelligence and Technology Collaboratory for Aging Research (JH AITC)
Director, Gerotech Incubator & Translational Aging Research Training Program

Dr. Peter Abadir is a physician-scientist and geriatrician at Johns Hopkins University, where he serves as Co-Principal Investigator of the Johns Hopkins Artificial Intelligence and Technology Collaboratory for Aging Research (JH AITC). This national center, funded by the National Institute on Aging, promotes the development and implementation of novel AI and technology-driven solutions to improve the health and independence of older adults. Under Dr. Abadir’s leadership, the AITC provides pilot funding, stakeholder engagement infrastructure, and AI expertise to investigators and startups working to translate innovations into practical tools, especially for underserved communities and individuals affected by Alzheimer’s Disease and related conditions.

Dr. Abadir’s own research bridges geriatrics, molecular biology, and engineering. His work has contributed to the discovery of the mitochondrial angiotensin system, novel biomarkers of frailty and cognitive decline, and the design of targeted therapeutics using nanotechnology. He directs the Gerotech Incubator, a program integrating engineering and medicine to develop aging-focused technologies, and co-directs the Translational Aging Research Training Program (T32), mentoring the next generation of interdisciplinary aging researchers.

Dr. Abadir also serves as Deputy Editor of the Journal of the American Geriatrics Society. Across his roles, he advances innovation at the intersection of artificial intelligence, clinical care, and aging science.

Dr. Abadir’s research explores the molecular underpinnings of frailty and aging-related vulnerability, with a particular emphasis on chronic inflammation, metabolic dysfunction, and the role of the renin-angiotensin system in vascular aging. He leads NIH-funded studies investigating epigenetic and proteomic biomarkers, including circulating cell-free DNA and metabolomic signatures, to identify biologically distinct frailty subtypes and inform targeted interventions. His lab also focuses on the integration of systems biology with clinical phenotyping to bridge molecular findings with real-world functional outcomes in aging populations.

Complementing this molecular approach, Dr. Abadir leads innovative efforts to harness artificial intelligence and wearable/non-contact sensors to quantify frailty and aging phenotypes. His team applies machine learning to digital biosignals—including gait, voice, handwriting, and eye tracking—to develop novel biomarkers of cognitive and physical decline. These tools are designed to support early detection, risk stratification, and personalized care planning for older adults in diverse settings, from homes to hospitals.